PGNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Progenics Pharmaceuticals Inc's cash flow from others for the three months ended in Mar. 2016 was $0.08 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Mar. 2016 was $1.26 Mil.
Cash flow from others may include changes in working capital.
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).
Progenics Pharmaceuticals Inc Cash Flow from Others for the trailing twelve months (TTM) ended in Mar. 2016 was 0.788 (Jun. 2015 ) + -0.179 (Sep. 2015 ) + 0.569 (Dec. 2015 ) + 0.084 (Mar. 2016 ) = $1.26 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
Progenics Pharmaceuticals Inc Annual Data
|Cash Flow from Others||25.99||-0.00||0.97||0.98||-0.01||0.00||-0.33||0.92||3.99||1.60|
Progenics Pharmaceuticals Inc Quarterly Data
|Cash Flow from Others||0.35||0.46||0.29||0.80||1.45||0.30||0.79||-0.18||0.57||0.08|